Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer

Probiotic roles of Clostridium butyricum (C.B) are involved in regulating disease and cancers, yet the mechanistic basis for these regulatory roles remains largely unknown. Here, we demonstrate that C.B reprograms the proliferation, migration, stemness, and tumor growth in CRC by regulating pivotal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gut microbes Ročník 15; číslo 1; s. 2186114
Hlavní autoři: Xu, Hui, Luo, Haidan, Zhang, Jiayu, Li, Kai, Lee, Mong-Hong
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Taylor & Francis 31.12.2023
Taylor & Francis Group
Témata:
5-FU
Anti-PD1
Cell Line, Tumor
Cell Proliferation
Clostridium butyricum
Colorectal Neoplasms - pathology
Fluorouracil - pharmacology
Fluorouracil - therapeutic use
Gastrointestinal Microbiome
Humans
immunotherapy
MYC
Research Paper
TYMS
ubiquitination
Clostridium butyricum
ubiquitination
MYC
immunotherapy
Anti-PD1
TYMS
5-FU
ISSN:1949-0976, 1949-0984, 1949-0984
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Probiotic roles of Clostridium butyricum (C.B) are involved in regulating disease and cancers, yet the mechanistic basis for these regulatory roles remains largely unknown. Here, we demonstrate that C.B reprograms the proliferation, migration, stemness, and tumor growth in CRC by regulating pivotal signal molecules including MYC. Destabilization of MYC by C.B supplementation suppresses cancer cell proliferation/metastasis, sensitizes 5-FU treatment, and boosts responsiveness of anti-PD1 therapy. MYC is a transcriptional regulator of Thymidylate synthase (TYMS), a key target of the 5-FU. Also MYC is known to impact on PD-1 expression. Mechanistically, C.B treatment of CRC cells results in MYC degradation by enhancing proteasome-mediated ubiquitination, thereby mitigating MYC-mediated 5-FU resistance and boosting anti-PD1 immunotherapeutic efficacy. Together, our findings uncover previously unappreciated links between C.B and CRC cell signaling, providing insight into the tumorigenesis modulating mechanisms of C.B in boosting chemo/immune therapies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-0976
1949-0984
1949-0984
DOI:10.1080/19490976.2023.2186114